Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial
Journal of Clinical Oncology · 2026
DOI: 10.1200/jco-25-02842 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Run-Cong Nie und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical R…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Esophagogastric Junction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The NEOSUMMIT-01 trial previously showed that adding the PD-1 antibody toripalimab to perioperative chemotherapy improved the pathologic response in patients with locally advanced gastric or gastroesophageal junction cancer. Here, we present the event-free survival (EFS) and overall survival (OS) after extended follow-up. A total of 108 patients were enrolled (toripalimab plus chemotherapy, n = 54; chemotherapy alone, n = 54). At the data cutoff date (August 29, 2025), the median follow-up was 43.2 months (interquartile range: 36.6-53.7). The 3-year EFS was 74.7% (95% CI, 63.6% to 87.7%) in the toripalimab plus chemotherapy group and 56.2% (95% CI, 43.3% to 73.0%) in the chemotherapy group, with a hazard ratio (HR) of 0.51 (95% CI, 0.27 to 0.98; P = .044). The 3-year OS was 81.3% (95% CI, 71.4% to 92.4%) versus 72.2% (95% CI, 61.2% to 85.2%), respectively, with an HR of 0.45 (95% CI, 0.21 to 0.95; P = .036). The survival benefits were consistent across most predefined subgroups and were maintained in the analysis excluding patients with dMMR. In conclusion, perioperative toripalimab plus chemotherapy significantly improved 3-year EFS and OS compared with chemotherapy alone, suggesting it as a promising treatment option for patients with locally advanced gastric or gastroesophageal junction cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, PR China.
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, PR China.
- Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, PR China.
- Department of Gastric Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China.
- Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, PR China.
- Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, PR China.
ORCID-Profile: Run-Cong Nie, Ying Jin, Yuan-Fang Li, Zi-Xian Wang, Hai-Bo Qiu, Mu-Yan Cai, Ji-Bin Li, Xiong-Wen Tang, Feng Wang, Rui-Hua Xu, Shu-Qiang Yuan
Zitieren
APA
Nie, R. C., Jin, Y., Liang, C. C., Li, Y. F., Chen, Y. B., Sun, X. W., Guan, W. L., Wang, Z. X., Qiu, H. B., Wang, W., Chen, S., Zhang, D. S., Ling, Y. H., Xi, S. Y., Cai, M. Y., Chi, J., Yang, Q. X., Liu, Z. M., Guan, Y. X., …, & Yuan, S. Q. (2026). Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02842
Vancouver
Nie RC, Jin Y, Liang CC, Li YF, Chen YB, Sun XW, et al. Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-02842
BibTeX
@article{Nie2026,
author = {Nie, Run-Cong and Jin, Ying and Liang, Cheng-Cai and Li, Yuan-Fang and Chen, Ying-Bo and Sun, Xiao-Wei and Guan, Wen-Long and Wang, Zi-Xian and Qiu, Hai-Bo and Wang, Wei and Chen, Shi and Zhang, Dong-Sheng and Ling, Yi-Hong and Xi, Shao-Yan and Cai, Mu-Yan and Chi, Jun and Yang, Qiu-Xia and Liu, Zhi-Min and Guan, Yuan-Xiang and Chen, Yong-Ming and Li, Ji-Bin and Tang, Xiong-Wen and Peng, Jun-Sheng and Wang, Feng and Zhou, Zhi-Wei and Xu, Rui-Hua and Yuan, Shu-Qiang},
title = {Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-25-02842}
}
EUVIMED